| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sammy Saab | Q88094221 |
| Edward W. Lee | Q41347543 | ||
| P2093 | author name string | Sung-Ki Cho | |
| Lourdes Alanis | |||
| P2860 | cites work | Side effects of yttrium-90 radioembolization | Q26821887 |
| Radioembolization with yttrium-90 microspheres work up: Practical approach and literature review | Q27009881 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization | Q28111719 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
| Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients | Q30892049 | ||
| Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization | Q33532957 | ||
| Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 | ||
| Radioembolization of hepatic tumors | Q33820777 | ||
| TREATMENT OF INOPERABLE PRIMARY PANCREATIC AND LIVER CANCER BY THE INTRA-ARTERIAL ADMINISTRATION OF RADIOACTIVE ISOTOPES (Y90 RADIATING MICROSPHERES). | Q34260705 | ||
| Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | Q34585175 | ||
| Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres | Q34609193 | ||
| Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. | Q34620919 | ||
| Radioembolization for hepatocellular carcinoma | Q34631431 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. | Q53391789 | ||
| Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. | Q53671257 | ||
| Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization | Q56603208 | ||
| Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis | Q57758019 | ||
| Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | Q57763422 | ||
| Internal radiation therapy of hepatic cancer | Q66958842 | ||
| Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors | Q71821807 | ||
| Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres | Q73093019 | ||
| Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging | Q81700730 | ||
| Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization | Q82436223 | ||
| A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization | Q84121312 | ||
| Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma | Q85064441 | ||
| Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? | Q86389913 | ||
| Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation | Q34982068 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization | Q35075280 | ||
| Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 | ||
| Prophylactic Embolization of the Cystic Artery Before Radioembolization: Feasibility, Safety, and Outcomes | Q35094057 | ||
| Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 | ||
| Technical aspects of radioembolization with 90Y microspheres. | Q36990908 | ||
| Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives | Q37068157 | ||
| Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. | Q37313269 | ||
| Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors | Q37373799 | ||
| Liver transplantation after radioembolization in a patient with unresectable HCC. | Q37625817 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. | Q37771838 | ||
| Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. | Q38039874 | ||
| Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience | Q38155625 | ||
| Staging systems of hepatocellular carcinoma: a review of literature | Q38207014 | ||
| Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma | Q38211814 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma | Q39318577 | ||
| Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery | Q40063283 | ||
| Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity | Q40192043 | ||
| Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. | Q40445560 | ||
| Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization | Q42145791 | ||
| Staging systems in hepatocellular carcinoma | Q42576509 | ||
| Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation | Q42601023 | ||
| Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction | Q43515372 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? | Q44126350 | ||
| Clinical practice in radioembolization of hepatic malignancies: a survey among interventional centers in Europe | Q44310956 | ||
| Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres | Q44692003 | ||
| Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. | Q45131304 | ||
| Use of yttrium-90 microsphere radioembolization of hepatocellular carcinoma as downstaging and bridge before liver transplantation: a case report. | Q46132216 | ||
| Biliary sequelae following radioembolization with Yttrium-90 microspheres | Q47746491 | ||
| Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis | Q47819721 | ||
| Liver disease induced by radioembolization of liver tumors: description and possible risk factors | Q47925759 | ||
| Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? | Q47991772 | ||
| Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital | Q49052349 | ||
| Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. | Q51300479 | ||
| Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. | Q51540114 | ||
| Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. | Q51593250 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | yttrium | Q941 |
| hepatocellular carcinoma | Q1148337 | ||
| microsphere | Q1759020 | ||
| drug carrier | Q3715494 | ||
| radiopharmaceutical | Q9178218 | ||
| liver neoplasm | Q18558073 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 472-88 | |
| P577 | publication date | 2016-01-01 | |
| 2016-06-27 | |||
| P1433 | published in | Korean journal of radiology : official journal of the Korean Radiological Society | Q26842124 |
| P1476 | title | Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review | |
| P478 | volume | 17 |
| Q64228978 | Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy |
| Q55003707 | Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas. |
| Q92760860 | Hypofractionated particle beam therapy for hepatocellular carcinoma-a brief review of clinical effectiveness |
| Q55283883 | Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know. |
| Q48328889 | New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. |
| Q39088419 | Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward |
| Q39144395 | Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab |
Search more.